It has been speculated that GD2 may promote malignant phenotypes in SCLC by recruiting ASC amino-acid transporter (ASCT2)—a major glutamine transporter that has an essential role in tumor growth and progression—to lipid rafts (glycolipid-enriched domains on the outer leaflet of the plasma membrane bilayer), leading to enhanced glutamine uptake through ASCT2 (12, 20). Here, SLC1A5 is linked to small cell lung carcinoma.